Technical Analysis for PCRX - Pacira Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | -0.46% | |
Lower Bollinger Band Walk | Weakness | -0.46% | |
Below Lower BB | Weakness | -0.46% | |
Lower Bollinger Band Touch | Weakness | -0.46% | |
Lower Bollinger Band Walk | Weakness | -2.95% | |
Inside Day | Range Contraction | -2.95% | |
Lower Bollinger Band Touch | Weakness | -2.95% | |
Oversold Stochastic | Weakness | -2.95% | |
Slingshot Bearish | Bearish Swing Setup | -3.31% | |
Pocket Pivot | Bullish Swing Setup | -3.31% |
Alert | Time |
---|---|
Rose Above Lower Bollinger Band | about 2 hours ago |
Fell Below Previous Day's Low | about 2 hours ago |
Fell Below Lower Bollinger Band | about 20 hours ago |
Down 2 % | about 21 hours ago |
Fell Below Previous Day's Low | about 22 hours ago |
Get a Trading Assistant
- Earnings date: 05/01/2024
Pacira Pharmaceuticals, Inc. Description
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers worldwide. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company markets EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic, indicated for administration into the surgical site to produce postsurgical analgesia; and DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a cancer of the immune system. Its product pipeline comprise EXPAREL that has completed Phase II clinical trials for postsurgical analgesia-nerve block administration; DepoNSAID, which is in preclinical trials for the relief of acute pain; and DepoMethotrexate that is in preclinical trials for the treatment of rheumatoid arthritis and oncology, as well as Bupivacaine Liposome Injectable Suspension for veterinary postsurgical analgesia. Pacira Pharmaceuticals, Inc. has a development and commercialization agreement, and related supply agreement with Aratana Therapeutics, Inc. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Cancer Pharmaceutical Immune System Pain Surgery Pharmaceutical Products Lymphoma Pharmacology Rheumatoid Arthritis Drug Delivery Suspension Nerve Acute Pain Drug Delivery Technology Bupivacaine Meningitis Piperidines Liposome Local Anesthetic Surgical Site Methotrexate
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 48.6 |
52 Week Low | 25.76 |
Average Volume | 497,006 |
200-Day Moving Average | 31.68 |
50-Day Moving Average | 29.05 |
20-Day Moving Average | 28.12 |
10-Day Moving Average | 27.35 |
Average True Range | 0.95 |
RSI (14) | 30.56 |
ADX | 29.39 |
+DI | 11.19 |
-DI | 25.39 |
Chandelier Exit (Long, 3 ATRs) | 27.53 |
Chandelier Exit (Short, 3 ATRs) | 28.62 |
Upper Bollinger Bands | 30.11 |
Lower Bollinger Band | 26.13 |
Percent B (%b) | -0.01 |
BandWidth | 14.15 |
MACD Line | -0.83 |
MACD Signal Line | -0.64 |
MACD Histogram | -0.1866 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 27.24 | ||||
Resistance 3 (R3) | 27.36 | 27.10 | 27.05 | ||
Resistance 2 (R2) | 27.10 | 26.81 | 27.04 | 26.99 | |
Resistance 1 (R1) | 26.60 | 26.63 | 26.47 | 26.48 | 26.92 |
Pivot Point | 26.34 | 26.34 | 26.28 | 26.28 | 26.34 |
Support 1 (S1) | 25.84 | 26.05 | 25.71 | 25.72 | 25.28 |
Support 2 (S2) | 25.58 | 25.87 | 25.52 | 25.21 | |
Support 3 (S3) | 25.08 | 25.58 | 25.15 | ||
Support 4 (S4) | 24.96 |